ID: ALA3234574

Max Phase: Preclinical

Molecular Formula: C25H30F3N7O

Molecular Weight: 501.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1CCN(c2cc(N3CCCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1

Standard InChI:  InChI=1S/C25H30F3N7O/c1-33-12-14-34(15-13-33)21-16-22(32-24(31-21)25(26,27)28)35-11-3-2-4-20(35)23(36)30-10-9-18-5-7-19(17-29)8-6-18/h5-8,16,20H,2-4,9-15H2,1H3,(H,30,36)/t20-/m0/s1

Standard InChI Key:  JNWZPZQICCVLFU-FQEVSTJZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 501.56

Molecular Weight (Monoisotopic): 501.2464

AlogP: 2.84

#Rotatable Bonds: 6

Polar Surface Area: 88.39

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 7.26

CX LogP: 4.90

CX LogD: 4.66

Aromatic Rings: 2

Heavy Atoms: 36

QED Weighted: 0.65

Np Likeness Score: -1.48

References

1. Phillips DP, Gao W, Yang Y, Zhang G, Lerario IK, Lau TL, Jiang J, Wang X, Nguyen DG, Bhat BG, Trotter C, Sullivan H, Welzel G, Landry J, Chen Y, Joseph SB, Li C, Gordon WP, Richmond W, Johnson K, Bretz A, Bursulaya B, Pan S, McNamara P, Seidel HM..  (2014)  Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.,  57  (8): [PMID:24666203] [10.1021/jm401731q]

Source

Source(1):

• Scientific Literature